Cost-effectiveness of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients

Clinical Infectious Diseases

Volumn 24, Issue 1, 1997, Pages 57-63

  McKinnon, Peggy S ^b   Paladino, Joseph A ^a   Grayson, M Lindsay ^b   Gibbons, Gary W ^b   Karchmer, Adolf W ^b  

^a Millard Fillmore Suburban Hospital   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; CILASTATIN; CILASTATIN PLUS IMIPENEM; IMIPENEM; SULBACTAM; SULTAMICILLIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIABETIC FOOT; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG COST; GANGRENE; HOSPITAL COST; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; OSTEOMYELITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEIZURE; TREATMENT FAILURE;

EID: 0031012226     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinids/24.1.57     Document Type: Article

References (27)

1. Gibbons GW, Marcaccio EJ Jr, Burgess AM, et al. Improved quality of diabetic foot care, 1984 vs 1990: Reduced length of stay and costs, insufficient reimbursement. Arch Surg 1993;128:576-81.
2. Apelqvist J, Ragnarson-Tennvall G, Persson U, Larsson J. Diabetic foot ulcers in a multidisciplinary setting: an economic analysis of primary healing and healing with amputation. J Intern Med 1994;235:463-71.
3. Bouter KP, Storm AJ, de Groot RR, Uitslager R, Erkelens DW, Diepersloot RJ. The diabetic foot in Dutch hospitals: epidemiological features and clinical outcome. Eur J Med 1993;2:215-8.
4. Lithner F. Epidemiology and economic impact of the diabetic foot - a major health care problem. In: Bakker K, Niewenhuijzen Kruseman AC, eds. The diabetic foot. Amsterdam: Excerpts Medica 1991:9-17.
5. Grayson ML, Gibbons GW, Habershaw GM, et al. Use of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients. Clin Infect Dis 1994;18:683-93.
6. Red book. Montvale, New Jersey: Medical Economics Data, 1994.
7. Drummond MF, Davies L. Economic analysis alongside clinical trials. Int J Technol Assess Health Care 1991;7:561-73.
8. de Lissovoy G, Elixhauser A, Luce BR, et al. Cost analysis of imipenemcilastatin versus clindamycin with tobramycin in the treatment of acute intra-abdominal infection. PharmacoEconomics 1993;4:203-14.
9. Paladino JA, Fell RE. Pharmacoeconomic analysis of cefmenoxime dual individualization in the treatment of nosocomial pneumonia. Ann Pharmacother 1994;28:384-9.
10. Paladino JA. Comparison of cefepime and ceftazidime using decision analysis. PharmacoEconomics 1994;5:505-12.
11. Atkinson HC, Chambers ST, McGinlay AM. Antibiotic therapy cost. N Z Med J 1989;102:409-11.
12. Foran RM, Brett JL, Wulf PH. Evaluating the cost impact of intravenous antibiotic dosing frequencies. DICP, Ann Pharmacother 1991;25:546-51.
13. Plumridge RJ. Cost comparison of intravenous antibiotic administration. Hosp Pharm 1991;26:600,603-4,615.
14. Tanner DJ. Cost containment of reconstituted parenteral antibiotics: personnel and supply costs associated with preparation, dispensing, and administration. Rev Infect Dis 1984;6(suppl 4):S924-37.
15. The American Hospital Association Hospital Statistics, 1992-3. Chicago: American Hospital Association, 1993:7.
16. Detsky AS. Guidelines for economic analysis of pharmaceutical products: a draft document for Ontario and Canada. PharmacoEconomics 1993;3:354-61.
17. Bootman JL, Larson LN, McGhan WF, et al. Pharmacoeconomic research and clinical trials: concepts and issues. DICP, Ann Pharmacother 1989;23:693-7.
18. Criado E, DeStefano AA, Keagy BA, Upchurch GR, Johnson G. The course of severe foot infection in patients with diabetes. Surg Gynecol Obstet 1992;175:135-40.
19. Seabrook GR, Edmiston CE, Schmitt DD, Krepel C, Bandyk DF, Towne JB. Comparison of serum and tissue antibiotic levels in diabetes-related foot infections. Surgery 1991;110:671-7.
20. Calhoun JH, Eng M, Cantrell J, et al. Treatment of diabetic foot infections: Wagner classification, therapy, and outcome. Foot Ankle 1988;9:101-6.
21. Asfar SK, Al-Arouj M, Al-Nakhi A, Baraka A, Juma T, Johny M. Foot infections in diabetics: the antibiotic choice. Can J Surg 1993;36:170-2.
22. Sapico FL, Witte JL, Canawati UN, Montgomerie JZ, Bessman AN. The infected foot of the diabetic patient: quantitative microbiology and analysis of clinical features. Rev Infect Dis 1984;6(suppl 1):S171-6.
23. Hunt JA. Foot infections in diabetes are rarely due to a single microorganism. Diabetic Medicine 1992;9:749-52.
24. Joseph WS. Treatment of lower extremity infections in diabetics. Drugs 1991;42:984-96.
25. Erlich KS, Rumack JS. Evaluation and management of nonhealing infected wounds in diabetics. Infect Med 1993;10:21-7.
26. Brodsky JW, Schneidler C. Diabetic foot infections. Ortho Clin North Am 1991;22:473-89.
27. Lipsky BA, Pecoraro RE, Wheat LJ. The diabetic foot: soft tissue and bone infection. Infect Dis Clin North Am 1990;4:409-32.